EpiPen

Pharmalot By Ed Silverman

Hospitals are itching for a share of the Mylan settlement over Medicaid rebates

Pharmalot By Ed Silverman

West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant looks to sell Salix to lessen debt load

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement

Pharmalot By Ed Silverman

An EpiPen alternative is about to return to your local pharmacy

Pharmalot By Ed Silverman

EpiPen prescriptions continue to climb, but market share dropped

Pharmalot By Ed Silverman

Elizabeth Warren criticizes feds for a ‘shamefully weak’ deal with Mylan

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

The Pharmalot View By Ed Silverman

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens

Pharmalot By Ed Silverman

Mylan to pay $465 million to settle claims of shortchanging Medicaid

Pharmalot By Ed Silverman

Mylan overcharged Medicaid for EpiPen for years, despite warnings

First Opinion By Jennifer Brokaw

Cheap EpiPen alternative risks patients’ lives. I’ve seen it myself

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers

Pharmalot By Ed Silverman

Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war